Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Horizon Therapeutics (NQ: HZNP )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Horizon Therapeutics

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
New Analysis of UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in Neurology Neuroimmunology & Neuroinflammation
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Elizabeth H.Z. Thompson as a Healthcare Businesswomen’s Association 2021 Luminary
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics PLC (HZNP) Q1 2021 Earnings Call Transcript
HZNP earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Horizon Earnings Miss, Revenue Tops
Horizon Therapeutics earnings fell short of Q1 estimates though revenue beat views. The biotech raised its 2021 revenue target. 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Recap: Horizon Therapeutics Q1 Earnings
Shares of Horizon Therapeutics (NASDAQ:HZNP) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were down 92.50% year over year to $... 
Via Benzinga
Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Net Sales Guidance and Full-Year Adjusted EBITDA Guidance to Incorporate Recently Acquired Viela Bio, Inc.
From Horizon Therapeutics plc
Via Business Wire
Biotech Cel-Sci Stock Joins Rank Of Stocks With RS Ratings Over 90
Cel-Sci shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Biotech Applied Molecular Transport Stock Earns Relative Strength Rating Upgrade
On Tuesday, Applied Molecular Transport stock reached an important technical milestone, seeing its Relative Strength Rating jump to 91 from 87. 
Via Investor's Business Daily
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... 
Via Benzinga
Horizon Therapeutics plc Ranks Among the Top Companies in Overall Corporate Reputation in 2020 PatientView Survey of Patient Organizations Worldwide
From Horizon Therapeutics plc
Via Business Wire
The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 26) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
3 Reasons to Buy Horizon Therapeutics Stock and 1 Not To
Horizon Therapeutics's shares are up almost 200% over the past 12 months, buoyed by mind-boggling sales of its new blockbuster drug. 
Via The Motley Fool
New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics
Via Business Wire
New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For®
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Release First-Quarter 2021 Financial Results and Host Webcast on May 5, 2021
From Horizon Therapeutics plc
Via Business Wire
RECIPE Randomized Controlled Trial Data Published in Arthritis & Rheumatology Show Higher Response Rates Using KRYSTEXXA® (pegloticase injection) with the Immunomodulator Mycophenolate Mofetil
From Horizon Therapeutics plc
Via Business Wire
Does 2021's Best Biopharma to Work for Belong in Your Portfolio?
Horizon Therapeutics has a clear path to significant sales growth. 
Via The Motley Fool
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.